196 related articles for article (PubMed ID: 10463589)
1. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ
Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589
[TBL] [Abstract][Full Text] [Related]
2. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
Wandel C; Kim RB; Guengerich FP; Wood AJ
Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
[TBL] [Abstract][Full Text] [Related]
3. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds.
Yumoto R; Murakami T; Nakamoto Y; Hasegawa R; Nagai J; Takano M
J Pharmacol Exp Ther; 1999 Apr; 289(1):149-55. PubMed ID: 10086998
[TBL] [Abstract][Full Text] [Related]
4. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
[TBL] [Abstract][Full Text] [Related]
5. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Zhang Y; Guo X; Lin ET; Benet LZ
Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
7. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.
Perloff ES; Duan SX; Skolnik PR; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2005 Jun; 33(6):764-70. PubMed ID: 15764714
[TBL] [Abstract][Full Text] [Related]
8. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Ma B; Prueksaritanont T; Lin JH
Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
[TBL] [Abstract][Full Text] [Related]
9. Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole.
Gibbs MA; Kunze KL; Howald WN; Thummel KE
Drug Metab Dispos; 1999 May; 27(5):596-9. PubMed ID: 10220488
[TBL] [Abstract][Full Text] [Related]
10. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
11. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
Danie WA; Syrek M; Ryłko Z; Wójcikowski J
Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
[TBL] [Abstract][Full Text] [Related]
12. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.
Hochman JH; Chiba M; Yamazaki M; Tang C; Lin JH
J Pharmacol Exp Ther; 2001 Jul; 298(1):323-30. PubMed ID: 11408558
[TBL] [Abstract][Full Text] [Related]
14. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe.
Chauret N; Tremblay N; Lackman RL; Gauthier JY; Silva JM; Marois J; Yergey JA; Nicoll-Griffith DA
Anal Biochem; 1999 Dec; 276(2):215-26. PubMed ID: 10603245
[TBL] [Abstract][Full Text] [Related]
15. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues.
Matheny CJ; Ali RY; Yang X; Pollack GM
Drug Metab Dispos; 2004 Sep; 32(9):1008-14. PubMed ID: 15319343
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
17. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
18. Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats.
Machavaram KK; Gundu J; Yamsani MR
Pharmazie; 2004 Dec; 59(12):957-60. PubMed ID: 15638086
[TBL] [Abstract][Full Text] [Related]
19. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
[TBL] [Abstract][Full Text] [Related]
20. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
